Another article accepted for publication!
This Phase 2 trial was designed to investigate the usefulness of immunotherapy in the second-line setting for the management of malignant pleural mesothelioma. Immunotherapy via checkpoint inhibitors is aimed to mobilize the patient’s own immune defenses against hostile tumor cells. This mechanism of action differs from that of standard chemothdrapeutic agents that act by directly attacking the tumor cells by inhibiting cell devision. The results of this Phase 2 study appear very promising, and large-scale Phase 3 trials are now required for further supporting clinical evidence.
We couldn’t be more thrilled about this latest success, and would like to encourage you too to entrust your work to us, no matter where you currently are in the writing process! We take on projects from conception right up to submission, as well as polishing near-complete work, as this publishing success story proves!